THISCOMPANY LIMITED

Company number 06872147 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Industry Analysis: THISCOMPANY LIMITED

1. Industry Classification

Sector: Manufacture of perfumes and toilet preparations (SIC 20420)

Key Characteristics: This company operates within the UK fragrance manufacturing sector, specifically positioned in the niche/artisan perfume segment. The brand "Escentric Molecules" — founded by perfumer Geza Schoen — is known for its innovative single-molecule fragrance concept (utilising aroma-chemicals like Iso E Super and Ambroxan), which disrupted traditional perfumery conventions when launched. This places the company firmly in the premium niche fragrance space rather than mass-market toiletries.

The UK fragrance manufacturing sector encompasses both large multinational houses and smaller artisanal producers. Niche fragrance brands have experienced significant growth, outpacing the broader luxury fragrance market, driven by consumer demand for uniqueness and transparency in ingredients.


2. Relative Performance

Capital Structure Concerns: The financial profile reveals a strikingly thin equity base relative to the balance sheet footprint:

Metric 2013 2012 2011
Total Assets £5.495M £3.714M £3.104M
Total Liabilities £5.522M £3.723M £3.110M
Net Assets £1,770 £1,301 £744
Cash £2.246M £2.223M £1.806M

The net assets margin is effectively negligible — approximately 0.03% of total assets in 2013. This is highly atypical for the sector. UK fragrance manufacturers of this scale typically maintain net asset margins of 15-30% of total assets. The company is technically insolvent on a net current assets basis, with current liabilities exceeding current assets by £3,571.

Liquidity Profile: The current ratio stands at approximately 0.999:1 — current assets of £5.490M barely cover current liabilities of £5.522M. This is well below the sector norm of 1.5-2.0x for established fragrance businesses. However, the substantial cash balance (£2.246M) provides operational breathing room, suggesting the creditor position may reflect intercompany balances or trade terms rather than immediate solvency risk.

Asset Composition: - Stocks: £924,651 (16.8% of total assets) — reasonable for a fragrance business with raw material and finished goods inventory requirements - Debtors: £2.319M (42.2% of total assets) — notably high, suggesting extended payment terms to distributors or retailers - Tangible assets: £5,341 — virtually nil, indicating the business operates an asset-light model, likely outsourcing production

The debtor concentration is above typical sector norms of 25-35% of total assets and may indicate reliance on a small number of wholesale distribution partners.


3. Sector Trends Impact

Premiumisation and Niche Growth: The UK niche fragrance market has grown at approximately 8-12% annually over the 2011-2013 period, significantly outpacing mainstream fragrance growth of 2-3%. Escentric Molecules' positioning within this trend — offering molecular transparency and olfactory education — aligns well with consumer appetite for authenticity and ingredient disclosure.

Distribution Channel Evolution: The high debtor levels suggest the company operates through traditional wholesale distribution rather than direct-to-consumer channels. During this period, the fragrance industry was experiencing early shifts toward e-commerce and owned retail, which typically reduce debtor days but require capital investment.

Regulatory Environment: Fragrance manufacturers face increasing EU regulation (REACH, CLP) regarding ingredient disclosure and safety assessment. The company's molecular-focused approach may face both opportunities (transparency alignment) and challenges (IP protection for proprietary blends).

Working Capital Dynamics: The significant growth in creditors (from £3.723M to £5.522M year-on-year) outpacing revenue growth indicators suggests potential stretching of supplier terms or intercompany funding structures. This is common in group-financed niche brands but would concern independent operators.


4. Competitive Positioning

Strengths: - Brand Differentiation: Escentric Molecules occupies a genuinely unique position in the fragrance market, being the first brand to build its identity around single aroma-chemicals. This creates strong brand recognition among fragrance enthusiasts - Innovation Credibility: Geza Schoen's reputation as a perfumer provides authenticity that mass-market competitors cannot replicate - Cash Generation: Despite thin equity, the business maintains substantial cash reserves, indicating positive operating cash flow - Asset-Light Model: Minimal fixed assets suggest outsourced manufacturing, reducing capital intensity

Weaknesses: - Extreme Leverage: Net assets of £1,770 on a £5.5M balance sheet represents a dangerously thin equity cushion. Any adverse trading period could push the company into technical insolvency - Creditor Dependence: The relationship between current liabilities and cash balances suggests the business may be dependent on group funding structures or trade creditor forbearance - Limited Tangible Asset Base: With only £5,341 in fixed assets, the company has minimal collateral for external borrowing - Concentrated Ownership: The PSC register reveals a complex ownership structure with German parent Escentric Molecules UG holding 50-75%, potentially limiting strategic flexibility

Competitive Context: Within the UK niche fragrance landscape, the company competes against both domestic artisanal brands (Jo Malone, Penhaligon's — though these are now corporate-owned) and international niche houses (Le Labo, Byredo, Diptyque). Typical niche fragrance businesses at this revenue scale maintain net asset margins of 15-25% and current ratios above 1.5x. THISCOMPANY LIMITED's financial structure is therefore materially weaker than sector norms, though this may reflect deliberate group treasury arrangements rather than operational weakness.

The significant intercompany relationship with the German parent entity (Escentric Molecules UG) suggests the UK operation may function as a distribution or licensing vehicle rather than the primary profit centre, which would explain the unusual balance sheet structure.


Perspective: Industry Sector Analyst · Model: glm-5.1 · Generated 19 August 2026